AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1390955 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 59
Study 3909331 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1‐2 g administered intravenously three or four times daily)
Number of subjects: 113
Study 3909331 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 113
Study 3909331 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (3‐5 mg/kg per day)
Number of subjects: 113
Study 31165898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand Up Victoria intervention
Number of subjects: 231
Study 31165898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study 29339395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg once a day for 5 days (FINA05)
Number of subjects: 193
Study 29339395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg once a day for 10 days (FINA10)
Number of subjects: 193
Study 29339395 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg/500 mg twice a day for 10 days (CIPRO10)
Number of subjects: 193
Study 29339395 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (CIPRO10)
Number of subjects: 193
Study 29339395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (FINA05 and FINA10)
Number of subjects: 193
Study 29339395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (FINA05)
Number of subjects: 193
Study 29339395 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin (FINA10)
Number of subjects: 193
Study 27575452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) with thoracic epidural levobupivacaine 0.12% plus sufentanil 0.4 µg/mL for 48 hours
Number of subjects: 51
Study 27575452 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration and continuous infusion with local anesthetics plus a single morphine bolus (CWI‐M) with 10 mL levobupivacaine 0.5% and levobupivacaine 0.25% infusion for 48 hours
Number of subjects: 51
Study 24816038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 5244
Study 23226717 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating contingency management (CM) schedule
Number of subjects: 90
Study 23226717 — intervention group
Group type: COMPARATOR
Intervention: Fixed contingency management (CM) schedule
Number of subjects: 90
Study 20192531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to represent 2 states of affairs
Number of subjects: 186
Study 20192531 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing negation in the context of an inconsistency
Number of subjects: 186
Study 18375319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (1 mL, 0.1 mg)
Number of subjects: 2
Study 18375319 — intervention group
Group type: COMPARATOR
Intervention: NaCl (1 mL)
Number of subjects: 2
Study 11493736 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐‐CSF plus dexamethasone
Number of subjects: 20
Study 11493736 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐‐CSF alone
Number of subjects: 20
Study 11493736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 20
Study 11493736 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 20
Study 9561271 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiadhesion device, a thin, filmy membrane composed of two organic substances that are resorbed by the body, inserted intraoperatively between apposing tissue surfaces.
Number of subjects: 0
Study 7827630 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 40
Study 7827630 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body ergometry
Number of subjects: 40
Study 7827630 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent electrical stimulation
Number of subjects: 40
Study 7827630 — intervention group
Group type: COMPARATOR
Intervention: Control (rest after exercise)
Number of subjects: 40
Study 3048153 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg
Number of subjects: 52
Study 3048153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31785250 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg of nalbuphine
Number of subjects: 60
Study 31785250 — intervention group
Group type: COMPARATOR
Intervention: 2.5 μg/kg of sufentanil
Number of subjects: 60
Study 29952216 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE CHF-PC intervention (in-person palliative care assessment, weekly telehealth coaching sessions, monthly follow-up)
Number of subjects: 8
Study 28384315 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine-self strategy
Number of subjects: 63
Study 28384315 — intervention group
Group type: COMPARATOR
Intervention: Imagine-other strategy
Number of subjects: 63
Study 28384315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 26043228 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks
Number of subjects: 37
Study 26043228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GLP-1 RA treatment)
Number of subjects: 37
Study 23434881 — intervention group
Group type: EXPERIMENTAL
Intervention: Studying a misspelling
Number of subjects: 0
Study 23434881 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing spelling recognition in an old context
Number of subjects: 0
Study 23434881 — intervention group
Group type: EXPERIMENTAL
Intervention: Words studied misspelled
Number of subjects: 0
Study 21641776 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil (150 mg/d)
Number of subjects: 60
Study 21641776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19621342 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge software
Number of subjects: 631
Study 19621342 — intervention group
Group type: COMPARATOR
Intervention: Usual care, handwritten discharge
Number of subjects: 631
Study 17012108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (45 mg daily)
Number of subjects: 34
Study 17012108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (45 mg daily) plus Vitamin D3 (0.75 microg 1alpha‐hydroxyvitamin D3 daily)
Number of subjects: 34
Study 15271700 — intervention group
Group type: COMPARATOR
Intervention: IV bolus of phenylephrine (50‐100 microg) or nitroglycerine (300‐500 microg)
Number of subjects: 42
Study 15271700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion of 500 mL of a gelatin solution
Number of subjects: 42
Study 10669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy (60 Gy at 2.0 Gy per fraction)
Number of subjects: 458
Study 10669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (1.2 Gy per fraction delivered twice daily to a total dose of 69.6 Gy)
Number of subjects: 458
Study 10669675 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation (2.0 Gy per fraction to 60 Gy)
Number of subjects: 458
Study 9193736 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP (0.25 mg/kg body weight)
Number of subjects: 17
Study 9193736 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP
Number of subjects: 17
Study 9193736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8437010 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dextromethorphan daily for 12 weeks
Number of subjects: 14
Study 8437010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dextromethorphan daily for up to 6 months
Number of subjects: 14
Study 8437010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30686699 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1,000 mg before LTx and 250 mg every other day from Day 1 to Day 31 after LTx)
Number of subjects: 68
Study 30686699 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 68
Study 30686699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 28606190 — intervention group
Group type: EXPERIMENTAL
Intervention: Public reporting of prescription indicators monthly for one year
Number of subjects: 31460
Study 26573140 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC)
Number of subjects: 176
Study 26573140 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 176
Study 23142856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile VCT in rural Vulindlela
Number of subjects: 1015
Study 23142856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile VCT in urban Soweto
Number of subjects: 1015
Study 23142856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile VCT in both sites
Number of subjects: 1015
Study 21172721 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 150 mg
Number of subjects: 131
Study 21172721 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 300 mg
Number of subjects: 131
Study 21172721 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (no treatment, aspirin 75‐325 mg or clopidogrel 75 mg once daily)
Number of subjects: 131
Study 21172721 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 150 mg and 300 mg
Number of subjects: 131
Study 18662422 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care intervention
Number of subjects: 0
Study 18662422 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16829673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 40
Study 16829673 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 14742786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose amoxicillin (80-90 mg/kg/d)
Number of subjects: 0
Study 14742786 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose amoxicillin (40-45 mg/kg/d)
Number of subjects: 0
Study 11275035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg tablet every 4 hours for a maximum of six doses)
Number of subjects: 111
Study 11275035 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Foley catheter (30‐mL Foley catheter placed transcervically with maintenance of traction)
Number of subjects: 111
Study 11275035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 111
Study 9313739 — intervention group
Group type: EXPERIMENTAL
Intervention: Power colour flow
Number of subjects: 16
Study 9313739 — intervention group
Group type: COMPARATOR
Intervention: Frequency based colour Doppler
Number of subjects: 16
Study 8439640 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 16
Study 8439640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2420386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctyl sodium sulfosuccinate (DS) administered 30 minutes before tetracycline and on -3, -2, and -1 day in the evening before tetracycline administration
Number of subjects: 3
Study 2420386 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline products (fast dissolving capsule, slow dissolving capsule, and suspension) without DS
Number of subjects: 3
Study 30158356 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 30158356 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban tosilate hydrate
Number of subjects: 0
Study 27405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion group (weekly emailed tips emphasizing social network interactions for walking)
Number of subjects: 308
Study 27405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity group (weekly tips + evidence‐based online fitness walking intervention)
Number of subjects: 308
Study 27405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Networks group (weekly tips + online networking site for walking)
Number of subjects: 308
Study 27405724 — intervention group
Group type: COMPARATOR
Intervention: All intervention groups
Number of subjects: 308
Study 24786143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency statin regimen (simvastatin 40 mg/day for 1 month, then simvastatin 80 mg/day)
Number of subjects: 8659
Study 24786143 — intervention group
Group type: COMPARATOR
Intervention: Delayed moderate-potency statin strategy (placebo for 4 months, then simvastatin 20 mg/day)
Number of subjects: 8659
Study 24786143 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8659
Study 24786143 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 8659
Study 24786143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency statin regimen
Number of subjects: 8659
Study 24786143 — intervention group
Group type: COMPARATOR
Intervention: Moderate-potency statin regimen
Number of subjects: 8659
Study 22672915 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group (VRG) - received three different Nintendo® Wii FIT balance interventions three times per week for 6 weeks
Number of subjects: 40
Study 22672915 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - received no intervention
Number of subjects: 40
Study 19652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-supplemented group (ISG) received 150 mg ferrous sulfate once weekly for 16 weeks.
Number of subjects: 193
Study 19652922 — intervention group
Group type: COMPARATOR
Intervention: Iron-unsupplemented group (IUG) received nothing.
Number of subjects: 193
Study 18813039 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg propofol plus 1.5 microg/kg remifentanil
Number of subjects: 98
Study 18813039 — intervention group
Group type: COMPARATOR
Intervention: 4.0 mg/kg propofol plus 0.5 microg/kg remifentanil
Number of subjects: 98
Study 16333242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 85
Study 12947367 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Sak at 0.01 mg/kg
Number of subjects: 378
Study 12947367 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Sak at doses of 0.01875 to 0.0375 mg/kg (n = 314)
Number of subjects: 378
Study 12947367 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Sak at 0.05 mg/kg (n = 23)
Number of subjects: 378
Study 12947367 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 378
Study 10371778 — intervention group
Group type: EXPERIMENTAL
Intervention: Creutzfeldt‐Jakob disease cases
Number of subjects: 26
Study 10371778 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 26
Study 8902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients preoperatively
Number of subjects: 123
Study 8902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients with advanced disease
Number of subjects: 123
Study 8902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients postoperatively with DVT
Number of subjects: 123
Study 8902990 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients postoperatively
Number of subjects: 123
Study 8902990 — intervention group
Group type: COMPARATOR
Intervention: Non-malignancy control group
Number of subjects: 123
Study 1853789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with vitamins A, C and E
Number of subjects: 30
Study 1853789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6352036 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-hydralazine combination (40 mg/25 mg, 80 mg/25 mg, 80 mg/50 mg, 120 mg/50 mg, 160 mg/50 mg, 160 mg/100 mg)
Number of subjects: 83
Study 6352036 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 83
Study 6352036 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 83
Study 6352036 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-hydralazine combination
Number of subjects: 83
Study 30648491 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-arm assisted THA
Number of subjects: 75
Study 30648491 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual THA
Number of subjects: 75
Study 30354641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Speed Rotational Atherectomy
Number of subjects: 0
Study 30354641 — intervention group
Group type: COMPARATOR
Intervention: Modified Balloons
Number of subjects: 0
Study 26856695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 40
Study 26856695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24864484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic electroneurostimulation (DENS)
Number of subjects: 2012
Study 22152430 — intervention group
Group type: EXPERIMENTAL
Intervention: Porridge with milk (Milk group)
Number of subjects: 274
Study 22152430 — intervention group
Group type: COMPARATOR
Intervention: Porridge with beef (Meat group)
Number of subjects: 274
Study 22152430 — intervention group
Group type: COMPARATOR
Intervention: Plain millet porridge (Plain group)
Number of subjects: 274
Study 21290831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Shuigou (GV 26), Neiguan (PC 6), and Sanyinjiao (SP 6)
Number of subjects: 102
Study 21290831 — intervention group
Group type: COMPARATOR
Intervention: Functional electric stimulation to stimulate the affected muscles of the upper limbs
Number of subjects: 102
Study 17998085 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbols for SOR presentation
Number of subjects: 84
Study 17998085 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbols for QOE presentation
Number of subjects: 84
Study 16521849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose (3 g ribose + 150 microg folate)
Number of subjects: 12
Study 16521849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mL)
Number of subjects: 12
Study 12521402 — intervention group
Group type: EXPERIMENTAL
Intervention: Active inhalers
Number of subjects: 400
Study 12521402 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers (control)
Number of subjects: 400
Study 10520911 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion
Number of subjects: 50
Study 10520911 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral infusion
Number of subjects: 50
Study 7486823 — intervention group
Group type: EXPERIMENTAL
Intervention: Boehmite (Rocgel)
Number of subjects: 64
Study 7486823 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (anti-H2)
Number of subjects: 64
Study 1778538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release acebutolol (500 mg/day)
Number of subjects: 10
Study 1778538 — intervention group
Group type: COMPARATOR
Intervention: Conventional acebutolol (200 mg tid)
Number of subjects: 10
Study 7035153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 71
Study 7035153 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 71
Study 30707227 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin suppression through levothyroxine therapy
Number of subjects: 867
Study 30707227 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 867
Study 30707227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral neck lymph node metastases
Number of subjects: 867
Study 30707227 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant metastases
Number of subjects: 867
Study 30707227 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated histology
Number of subjects: 867
Study 28424187 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 6 months
Number of subjects: 166
Study 28424187 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HabDiet) for 6 months (control)
Number of subjects: 166
Study 26407547 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out recruitment strategies (on-site recruitment)
Number of subjects: 1562
Study 26407547 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out recruitment strategies (routine care letters)
Number of subjects: 1562
Study 26407547 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in recruitment strategies
Number of subjects: 1562
Study 26407547 — intervention group
Group type: EXPERIMENTAL
Intervention: Relying on providers at the hospital (opt-in strategy)
Number of subjects: 1562
Study 23317340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture
Number of subjects: 54
Study 23317340 — intervention group
Group type: COMPARATOR
Intervention: Sham bee venom acupuncture
Number of subjects: 54
Study 21931661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg QD (Low)
Number of subjects: 30
Study 21931661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 250 mg QD (High)
Number of subjects: 30
Study 21931661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study 19150179 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 32
Study 19150179 — intervention group
Group type: COMPARATOR
Intervention: BMI-matched healthy controls
Number of subjects: 32
Study 17329466 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200-800 mg/day)
Number of subjects: 114
Study 17329466 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-30.0 mg/day)
Number of subjects: 114
Study 17329466 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1.5-6.0 mg/day)
Number of subjects: 114
Study 17329466 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 114
Study 15389983 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 0
Study 15389983 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10930903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. for 1 week (Group PAC)
Number of subjects: 69
Study 10930903 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg daily for 1 month (Group P)
Number of subjects: 69
Study 9207754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Convit vaccine plus MDT
Number of subjects: 125